Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes,has named Anthony Mottola as its Vice President of Managed Care and Market Access. A 16-year industry veteran, Mottola brings to Access an extensive pharmaceutical industry knowledge and experience in specialty pharmacy, healthcare services and reimbursement solutions. Anthony will lead the overall management of reimbursement and market access for MuGard within Access Pharmaceuticals.

Prior to joining Access, Anthony served as VP of Trade for BioScrip, where he developed customized distribution strategies, patient access and reimbursement programs to support the successful launch of various products, including MuGard. He was previously Associate Director National Accounts for Novartis, where he was responsible for the management and development of multiple national accounts, including Specialty Pharmacies, Reimbursement HUB Providers, Specialty distributors, GPO's, Managed Care Plans such as Cigna, Humana, Wellpoint and Government Organizations. Prior to Novartis, Anthony served in different capacities of sales management, mainly in the oncology area, at Pfizer, US Bioservices and Abbott Laboratories.

Anthony Mottola, Vice President Managed Care and Market Access, Access Pharmaceuticals, stated, "While working with Access at BioScrip, it became clear that MuGard was a superb product in a market relatively untapped by its competitors. I was encouraged to join Access by the enthusiastic patient and clinician support surrounding MuGard and its strong potential to become a market leader. I look forward to leveraging my experience and relationships to further strengthen Access' sound patient access program for MuGard."

"This appointment is an important step of our MuGard launch in the US," said Jeffrey Davis, CEO of Access Pharmaceuticals, Inc. He continued, "Anthony's hands-on development and reimbursement solutions expertise will be central to our efforts to further build out the necessary infrastructure and capability for the continued growth of our MuGard division."